Research & Development
Women's Health: Page 2
Breast cancer risk scores need to be adapted for men
Researchers at Vanderbilt-Ingram Cancer Center evaluated the utility of Oncotype DX (Genomic Health) recurrence scores in 848 men and 110,898 women with early-stage, estrogen receptor-positive (ER+) breast cancer. They used deidentified data from the National Cancer Database, which includes most new cancer cases in the U.S., and noted the recurrence risk score and mortality rate (Clin Cancer Res, November 20, 2019).
November 24, 2019
Older women miss out on cervical cancer screening
Practice guidelines suggest that between the ages of 30 and 65, women should undergo screening with an HPV test every five years or a Pap test every three years in consultation with their doctor.
November 10, 2019
Cheap vaginal-fluid testing signals risk for premature birth
The study involved noninvasive testing of 340 women in midtrimester pregnancy, with the goal of identifying two important signs of risk for preterm birth: depletion of Lactobacillus bacteria in the vaginal microbiome and short cervical length, defined as 25 mm. It was funded by grants from the Bill & Melinda Gates Foundation, the Brazilian Ministry of Health, and the Brazilian National Research Council.
October 21, 2019
Insurance claims study makes case for more prenatal blood testing
In the real-world study of claims data, Harvard Pilgrim Health Care and Illumina worked together to dramatically expand the use of prenatal blood testing to younger pregnant women while reducing the number of invasive tests, such as amniocentesis.
October 9, 2019
USPSTF renews support for routine hepatitis B screening
The statement on hepatitis B gives a grade A recommendation -- meaning the task force has high confidence in the evidence -- for routine screening with the hepatitis B surface antigen (HBsAg) test for all pregnant women. Ideally, testing should be performed in the first trimester, but it should at least be done in an early prenatal visit, according to Stanford University health policy expert Dr. Douglas Owens and colleagues on the task force (JAMA, July 23/30, 2019, Vol. 322:4, pp. 349-354).
July 22, 2019
LabCorp builds on consumer tests
The move represents an expansion of the company's Pixel by LabCorp direct-to-consumer platform, which now includes almost 90 lab tests, such as ones for cardiovascular health, diabetes and kidney function, and general wellness. Tests are also bundled into packages; for example, LabCorp has a women's health bundle. Consumers pay for testing through the company's Pixel website and then visit one of LabCorp's nearly 2,000 patient service centers in the U.S., which include locations at Walgreens pharmacies.
July 22, 2019
DNA forensic evidence frees Ohio man of rape, attempted rape
‘Good’ cholesterol worse for some adults: NIH study
Empatica receives FDA clearance for digital biomarker platform, closes Series B financing
AnchorDx enrolling U.S. clinical trial for bladder cancer assay
Week in Review: Elizabeth Holmes sentenced; good cholesterol worse for some adults; earlier type 2 diabetes diagnosis; and more
Chembio Diagnostics applies for FDA CLIA waiver for HIV, syphilis test
TAILORx update refines use of Oncotype DX breast cancer test
The update to the prospective, long-term Trial Assigning Individualized Options for Treatment (TAILORx) of almost 10,000 newly diagnosed breast cancer patients stresses the importance of assessing clinical risk, based on tumor size and histologic grade, in addition to results from the 21-gene Oncotype DX assay (Genomic Health) in women with early-stage, hormone receptor-positive/human epidermal growth factor receptor 2-negative, node-negative breast cancer.TAILORX update from @jsparano Arguably most important clinical data in breast cancer. “Benefit” of chemo in women
June 3, 2019
Page 2 of 2